We also show that a combined therapy of potassium channel blockers targeting KCa1.1 expressed by FLS and Kv1.3 expressed by TEM cells work in tandem to reduce disease severity in rat models of RA with more efficacy than monotherapy treatments. The gene discussed is KCNMA1; the disease is rheumatoid arthritis.